Minerva Surgical to Announce Fourth Quarter and Full-Year Financial Results
Minerva Surgical, a company specializing in women's health, has announced the release of its fourth quarter and full-year 2021 financial results on March 8, 2022. The event will include a conference call at 1:30 p.m. PT to discuss the results and recent business highlights. The company focuses on minimally invasive solutions for Abnormal Uterine Bleeding, aiming to provide alternatives to hysterectomy and address uterine healthcare needs. Access to the call will be available via telephone and online streaming.
- Focus on developing minimally invasive alternatives to hysterectomy.
- Broad product line addressing common causes of AUB.
- None.
SANTA CLARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full-year 2021 financial results on Tuesday, March 8, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (877) 804-7316 for domestic callers or (629) 228-0696 for international callers, using conference ID: 5577372. The live webinar of the call may be accessed by visiting the Recent Events section of the company’s website at http://ir.minervasurgical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.
ABOUT MINERVA SURGICAL – THE UTERINE HEALTH COMPANY
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
MEDIA CONTACT
Mike Clapper
mike.clapper@minervasurgical.com
804-295-7676
INVESTOR RELATIONS CONTACT
Caroline Corner
investors@minervasurgical.com
415-202-5678
RELATED LINKS
https://www.minervasurgical.com
FAQ
When will Minerva Surgical release its Q4 2021 financial results?
What is the purpose of the conference call on March 8, 2022?
How can I access the conference call for Minerva Surgical?
What does Minerva Surgical focus on?
